by Kadeja Johnson – RegMedNet –
4basebio PLC has received a Good Manufacturing Practice certification from the UK Medicine and Healthcare Regulatory Agency (London), authorizing the company to supply GMP-grade synthetic DNA as both a starting material and drug substance for clinical use in cell and gene therapies, as well as DNA- and mRNA-based vaccines.
4basebio’s COO, Amy Walker, commented on how 4basebio is leading the way in providing high-quality DNA products for use in clinical trials and commercialization.
